VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
5 awesome inventions to reduce troublesome Parkinson’s tremors
Specially designed products to stabilise shaking hands
1 month ago
Could a transplant lower the risk of Parkinson’s?
Researchers at Washington University School of Medicine, US, have found that having a heart, kidney, lung or bone marrow transplant could reduce the risk of developing Parkinson’s. As part of the study, published in medical journal ‘Parkinsonism & Related Disorders’, the team assessed data of just under 200,000 patients – 89,790 of whom had Parkinson’s. The results revealed that individuals who had a transplant were 37% less likely to develop Parkinson’s. This could be due to the immunosuppressant medication patients receive before undergoing a transplant, which researchers believe may help slow neurodegeneration as it reduces inflammation in the brain. The study said: “This study provides evidence that tissue transplant may be associated with a lower PD [Parkinson’s disease] risk, warranting further investigation to identify factors that mediate this relationship.”
A breakthrough Parkinson’s trial that featured in a two-part documentary on UK television channel BBC Two has published its results. The study, which featured in the documentary ‘The Parkinson’s Drug Trial: A miracle cure?’, aimed to investigate whether it was possible to restore damaged neurons by administering protein Glial Cell Line Derived Neurotrophic Factor (GDNF). As part of the trial, scientists initially infused GDNF into the brains of six participants living with the condition. Researchers then invited a further 35 individuals with Parkinson’s to take part, with approximately half being administered with a placebo infusion. Although not conclusive, the results suggest that GDNF had an impact on the brain and researchers believe the topic is worthy of further study. Dr Alan Whone, principal investigator on the trial, said: “This represents some of the most compelling evidence yet that we may have a means to possibly reawaken and restore the dopamine brain cells…
Course for Parkinson’s nurses launches in Slovenia
The International Parkinson and Movement Disorder Society is hosting its third summer school for nurses specialising in Parkinson’s. The course – which will be held from 10-12 May in Ljubljana, Slovenia – will focus on the management of the motor and non-motor symptoms of the condition. Students will also attend lectures, examine Parkinson’s patients and discuss treatment plans with experts. All lectures will be presented in English. Heather Vitale, senior programme manager at the International Parkinson and Movement Disorder Society, said: “This course offers a unique opportunity for nurses to enhance their knowledge in Parkinson’s disease, while also learning and networking with their peers through case study presentations and small group discussions.” Registration closes 26 April 2019 and costs USD $350.